Population pharmacokinetics of itraconazole in Thai HIV-1-Infected persons

Cees H. W. Koks, Alwin D. R. Huitema, Eugene D. M. B. Kroon, Theshinee Chuenyam, Rolf W. Sparidans, Joep M. A. Lange, Jos H. Beijnen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The authors describe the development of a population pharmacokinetic model using NONMEM for itraconazole and its active metabolite hydroxyitraconazole in a Thai cohort of HIV-infected patients who were using itraconazole as an addition to their antiretroviral therapy. The data were best described with an open two-compartment model for both itraconazole and hydroxyitraconazole. The model adequately described the data and provided population pharmacokinetic parameters which were not different from those described for other populations. The authors found that concomitant use of co-trimoxazole leads to a reduced formation rate (-51%) of hydroxyitraconazole
Original languageEnglish
Pages (from-to)229-233
JournalTherapeutic Drug Monitoring
Volume25
Issue number2
DOIs
Publication statusPublished - 2003

Cite this